ClinicalTrials.gg
CompletedNCT04165824Updated Jul 21, 2026Results posted

Safety Study of Oral Edaravone Administered in Subjects With ALS

A Phase 3 interventional study of MT-1186 in ALS, sponsored by Shionogi. Completed at 53 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Shionogi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
185
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral Sclerosis (ALS) over 24 and 48 weeks.

02

Conditions studied

  • ALS
03

In context

Lead sponsor

Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects will be male or female, ≥ 18 to 75 years of age at the time the ICF is signed
  • Subjects will be diagnosed with Definite ALS, Probable ALS, Probable laboratory-supported ALS, or Possible ALS according to the El Escorial revised criteria for the diagnosis of ALS.
  • Subjects will be living and functioning independently (eg, able to eat, excrete, ambulate independently without assistance of others). The use of supportive tools and adaptive utensil is allowed
  • Subjects will have a baseline forced vital capacity percentage (%FVC) ≥ 70%.
  • Subjects whose first symptom of ALS occurred within 3 years of the time of providing written .

Exclusion criteria

Exclusion Criteria:

  • Subjects who have the presence or history of any disease (except ALS) that could interfere with the objectives of the study (the assessment of safety and efficacy) or the safety of the subject, as judged by the Investigator.
  • Subjects of unwilling to use acceptable method of from the screening visit until 3 months after the last dose of study medication. Subjects who are sexually active who do not agree to use contraception during the study period.
  • Subjects who are female and pregnant (a positive pregnancy test) or lactating at the screening visit (Visit 1).
  • Subjects who have a significant risk of suicidality. Subjects with any suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with some intent to act, without a specific plan) or type 5 (active suicidal ideation with specific plan and intent) based on the Columbia-Suicide Severity Rating Scale (C-SSRS) within the 3 months before the screening visit.
  • Subjects who have or AST elevations greater than 2 times the at screening.
  • Subjects with a (GFR) \<30 mL/Min Per 1.73 m2.
  • Subjects with history of to edaravone, any of the additives or inactive ingredients of edaravone, or sulfites.
  • Subjects with hereditary fructose intolerance.
  • Subjects who participated in another study and were administered an product within 1 month or 5 half-lives of the investigational agent, whichever is longer before providing for the present study.
  • Subjects who are unable to take their medications orally.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
185 participants (actual)

Study arms

  • Experimental
    MT-1186

    Drug: MT-1186

Interventions

  • DrugMT-1186

    * An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug free period * Subsequent treatment cycles with daily dosing for 10 days out of a 14-day period, followed by a 14 day drug free period. Treatment cycles are every 4 weeks.

    Also known as: Oral edaravone

06

What researchers measure

Primary outcomes

  1. Number of Treatment Emergency Adverse Events

    Time frame: up to 48 Weeks

  2. Number of Participants With Treatment Emergency Adverse Events

    Time frame: Up to 48 Weeks

Other outcomes

  1. Change in ALS Functional Rating Scale - Revised From Baseline

    Time frame: up to 48 Weeks

  2. Time to Event (Death, Tracheostomy, and Permanent Assisted Mechanical Ventilation)

    Time frame: up to 48 Weeks

07

Results

Posted Aug 29, 2022

Participant flow

Participant flow — Overall Study
MilestoneMT-1186
Started185
Completed139
Not completed46
Withdrew: Adverse event23
Withdrew: Physician decision1
Withdrew: Withdrawal by subject17
Withdrew: Other5

Outcome measures

PrimaryNumber of Treatment Emergency Adverse Events
Time frame:
up to 48 Weeks
Reported as:
Number · events
Number of Treatment Emergency Adverse Events
eventsMT-1186
Number of Treatment Emergency Adverse Events961
PrimaryNumber of Participants With Treatment Emergency Adverse Events
Time frame:
Up to 48 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergency Adverse Events
ParticipantsMT-1186
Number of Participants With Treatment Emergency Adverse Events175
Other pre-specifiedChange in ALS Functional Rating Scale - Revised From Baseline
Time frame:
up to 48 Weeks

Results for this outcome have not been posted.

Other pre-specifiedTime to Event (Death, Tracheostomy, and Permanent Assisted Mechanical Ventilation)
Time frame:
up to 48 Weeks

Results for this outcome have not been posted.

Adverse events

Collected over up to 48 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MT-118612/185 (6.5%)48/185 (25.9%)123/185 (66.5%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventMT-1186
Amyotrophic lateral sclerosisNervous system disorders12/185
DysphagiaGastrointestinal disorders6/185
DyspnoeaRespiratory, thoracic and mediastinal disorders5/185
Respiratory failureRespiratory, thoracic and mediastinal disorders5/185
PneumoniaInfections and infestations4/185
Weight decreasedInvestigations2/185
FallInjury, poisoning and procedural complications2/185
CellulitisInfections and infestations1/185
Covid-19Infections and infestations1/185
Upper Respiratory Tract InfectionInfections and infestations1/185
Most frequent other events
Showing 10 of 15
Most frequent other events
EventMT-1186
FallInjury, poisoning and procedural complications40/185
Muscular weaknessMusculoskeletal and connective tissue disorders39/185
ConstipationGastrointestinal disorders33/185
Back painMusculoskeletal and connective tissue disorders19/185
DysphagiaGastrointestinal disorders16/185
InsomniaPsychiatric disorders16/185
DyspnoeaRespiratory, thoracic and mediastinal disorders16/185
ContusionInjury, poisoning and procedural complications15/185
FatigueGeneral disorders14/185
Muscle spasmsMusculoskeletal and connective tissue disorders13/185

Baseline characteristics

Age, Continuous
Age, Continuous(years)MT-1186
Mean59.9 ± 9.9
Age, Customized
Age, Customized(Participants)MT-1186
20 to 29 years1
30 to 39 years6
40 to 49 years19
50 to 59 years60
60 to 69 years63
>=70 years36
Sex: Female, Male
Sex: Female, Male(Participants)MT-1186
Female66
Male119
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MT-1186
Hispanic or Latino3
Not Hispanic or Latino177
Unknown or Not Reported5
08

Study locations

53 sites
  • St. Joseph's Hospital and Medical Center (SJHMC) - Barrow Neurological Institute (BNI) - The Gregory W. Fulton ALS and Neuromuscular Disease Center
    Phoenix, Arizona 85013, United States
  • Neuromuscular Research Center
    Phoenix, Arizona 85028, United States
  • Woodland Research Northwest
    Rogers, Arkansas 72758, United States
  • Sutter Health
    San Francisco, California 94115, United States
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • UF Health Cancer Center
    Gainesville, Florida 32610-3633, United States
  • Emory University - School of Medicine
    Atlanta, Georgia 30317-2819, United States
  • Johns Hopkins University
    Baltimore, Maryland 21205, United States
  • University of Michigan - ALS Center of Excellence
    Ann Arbor, Michigan 48109-5223, United States
  • University of Michigan Health System (UMHS) - Allergy Clinic - Northville Health Center Location
    Northville, Michigan 48168-9493, United States
  • Essentia Institute of Rural Health
    Duluth, Minnesota 55805, United States
  • Neurology Associates, P.C - Lincoln
    Lincoln, Nebraska 68506-2960, United States
  • Wake Forest University Baptist Medical Center (WFUBMC) - The J. Paul Sticht Center on Aging and Rehabilitation
    Winston-Salem, North Carolina 27157-0001, United States
  • Penn State Hershey Children's Hospital
    Hershey, Pennsylvania 17025, United States
  • Lewis Katz School of Medicine at Temple University
    Philadelphia, Pennsylvania 19140, United States
  • Alleghany General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • Wesley Neurology Clinic, P.C.
    Cordova, Tennessee 38018, United States
  • Texas Neurology, PA
    Dallas, Texas 75214, United States
  • Houston Methodist Neurological Institute
    Houston, Texas 77030, United States
  • UT Health Science Center San Antonio
    San Antonio, Texas 78229, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Heritage Medical Research Clinic - University Of Calgary
    Calgary, Alberta T2N 4Z6, Canada
  • University of Alberta - Walter C Mackenzie Health Sciences Centre (WCM)
    Edmonton, Alberta T6G 2B7, Canada
  • Recherche Sepmus, Inc
    Greenfield Park, Quebec J4V 2J2, Canada
  • Montreal Neurological Institute and Hospital
    Montreal, Quebec H3A 2B4, Canada
  • CHU Nice-Hospital Archet I
    Nice, Alpes Maritimes 06202, France
  • Centre Hospitalier Esquirol
    Limoges, Marcland 87025, France
  • Centre Hospitalier Universitaire (CHU) de Bordeaux
    Bordeaux, 33400, France
  • Hopital Pierre Wertheimer - Hopital Neurologique
    Bron, 69677, France
  • CHU de NICE Hopital Pasteur 2 -Centre de Reference des Maladies -Neuromusculaires & SLA-Pole Neurosciences Cliniques
    Nice, 6001, France
  • Deutsche Klinik fuer Diagnostik
    Wiesbaden, Hesse 65191, Germany
  • Medizinische Hochschule Hannover
    Hanover, Lower Saxony 30625, Germany
  • Ospedale San Raffaele (HSR) (Istituto Scientifico Universitario San Raffaele)
    Milan, MI 20132, Italy
  • Universita degli Studi di Torino - Centro Regionale Esperto Per La Sclerosi Laterale Amiotrofica (CRESLA)
    Turin, Piedmont 10126, Italy
  • Fondazione Serena Onlus - Azienda Ospedaliera Niguarda Ca Granda - Centro Clinico Nemo (Neuro Muscular Omnicentre)
    Milan, 20162, Italy
  • Aichi Medical University Hospital
    Nagakute-shi, Aichi-ken 480-1195, Japan
  • National Hospital Organization Chiba-East-Hospital
    Chiba, Chiba 260-8712, Japan
  • Murakami Karindoh Hospital
    Fukuoka, Fukuoka 819-8585, Japan
  • Fukushima Medical University Hospital
    Fukushima, Fukushima 960-1295, Japan
  • National Hospital Organization Hokkaido Medical Center
    Sapporo, Hokkaido 063-0005, Japan
  • National Hospital Organization Iou National Hospital
    Kanazawa, Ishikawa-ken 920-0192, Japan
  • Kagawa University Hospital
    Kita-gun, Kagawa-ken 761-0793, Japan
  • Kitasato University Hospital
    Sagamihara, Kanagawa 252-0375, Japan
  • Yokohama City University Hospital
    Yokohama, Kanagawa 236-0004, Japan
  • National Hospital Organization Kumamoto Saishun Medical Center
    Koshi-shi, Kumamoto 861-1196, Japan
  • National Hospital Organization Utano Hospital
    Kyoto, Kyoto 616-8255, Japan
  • Tohoku University Hospital
    Sendai, Miyagi 980-8574, Japan
  • Niigata University Medical And Dental Hospital
    Niigata, Niigata 951-8520, Japan
  • National Hospital Organization Toneyama Medical Center
    Toyonaka-shi, Osaka 560-8552, Japan
  • Shiga University of Medical Science Hospital
    Ōtsu, Shiga 520-2192, Japan
  • National Hospital Organization Shizuoka Institute of Epilepsy and Neurological Disorders
    Shizuoka, Shizuoka 420-8688, Japan
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo 113-8431, Japan
09

References and documents

Publications

  • Genge A, Pattee GL, Sobue G, Aoki M, Yoshino H, Couratier P, Lunetta C, Petri S, Selness D, Bidani S, Hirai M, Sakata T, Salah A, Apple S, Wamil A, Kalin A, Jackson CE. Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. Muscle Nerve. 2023 Feb;67(2):124-129. doi: 10.1002/mus.27768. Epub 2022 Dec 28. PubMed 36504406 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Oct 2021, 22 months.

Results were first posted in Aug 2022, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2019
First posted
Nov 18, 2019
StartActual
Nov 18, 2019
Primary completionActual
Oct 7, 2021
CompletionActual
Oct 7, 2021
Results first posted
Aug 29, 2022
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04165824
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Nov 18, 2019
Start date
Nov 18, 2019
Primary completion
Oct 7, 2021
Completion
Oct 7, 2021
Results posted
Aug 29, 2022
Last update
Jul 21, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion